title: [Successful treatment of haemodialysis-related porphyria cutanea tarda with deferoxamine].
abstract: BACKGROUND
  End-stage renal failure and long-term hemodialysis treatment promote porphyria cutanea tarda. Iron overload is often associated with this disease and is thought to play a role in its pathogenesis. We report a case of hemodialysis related-porphyria cutanea tarda improved by deferoxamine.
  
  
  METHODS
  A 45-year-old man, with end-stage renal failure and who had received hemodialysis treatment since 1993, presented a several months-history of blisters of the face and the dorsum of the hands. Laboratory analysis showed: hemoglobin 10 g/dl; a moderate hepatic cytolysis; ferritin 195 ng/l. HIV, HBV, HCV serologies were negative. Porphyries analyses showed a porphyria cutanea tarda pattern. The cutaneous histology was non specific; direct immunofluorescence was negative. The patient received deferoxamine (40 mg/kg intravenously every week for 6 weeks) which led to dramatic improvement of the symptoms.
  
  
  CONCLUSIONS
  Several treatments are proposed in the management of dialysis-related porphyria cutanea tarda. This case confirms that deferoxamine can induce rapid and prolonged remission.
authors.affiliation: Service de Dermatologie, CHU Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil.
authors.forename: P
authors.initials: P
authors.lastname: Pitche
authors.forename: E
authors.initials: E
authors.lastname: Corrin
authors.forename: P
authors.initials: P
authors.lastname: Wolkenstein
authors.forename: J
authors.initials: J
authors.lastname: Revuz
authors.forename: M
authors.initials: M
authors.lastname: Bagot
mesh_terms: D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D007502:Iron Chelating Agents; D003676:Deferoxamine